Chitosan improves the efficacy of gentamicin against MDR and biofilm-forming URO pathogenic E. coli
Keywords:
Biofilm, Chitosan, MIC-p, Chitosan-Graphene, MIC-b, MBEC, UPTis, TCP, APIAbstract
Uropathogenic E. coli is the most common cause of urinary tract infections (UTIs), accounting for 80-90% of community-acquired UTIs and 30-50% of hospital-acquired UTIs. Uropathogenic E. coli that form biofilms are linked to chronic and persistent inflammation, resulting in severe and recurring UTIs. Biofilms promote antibiotic resistance and the horizontal transfer of virulence genes, promoting the formation of multidrug-resistant organisms. This study aimed to combine low-molecular-weight chitosan with aminoglycoside gentamicin to improve its efficacy against biofilm formation and MDR E. coli. Different strains of bacteria were isolated from urine samples of different patients at the Ayub Teaching Hospital, Abbottabad, out of which 16 were identified as E. coli by API (Analytical Profile Index) 20E. The antibiotic sensitivity profile was determined using the disk diffusion method, and the results showed that a total of 10 isolates were found to be multidrug-resistant MDR (N=62.5%). Biofilm formation was tested using the TCP method, a total of 7 isolates were found to be strong biofilm producers (N=44%). Gentamicin exhibited the highest inhibitory activity against 10 isolates of E.coli, with MIC-p ranges of 4 and 2 µg/ml, respectively, while 6 isolates showed resistance to gentamicin with MIC-p ranges >512 µg/ml.
Downloads
References
Ansari, S., H.P. Nepal, R. Gautam, S. Shrestha, P. Neopane, G. Gurung and M.L. Chapagain. 2015. Community acquired multi-drug resistant clinical isolates of escherichia coli in a tertiary care center of nepal. Antimicrobial resistance and infection control, 4: 1-8.
Anusha, S. and S. Sundar. 2020. Esbl& biofilm-producing uropathogenic pathogens and their antibiotic susceptibility patterns from urinary tract infection of patients at namakkal, tamil nadu: A case study. Journal of Natural Remedies, 21(8 (1)): 381-387.
Breser, M.L., V. Felipe, L.P. Bohl, M.S. Orellano, P. Isaac, A. Conesa, V.E. Rivero, S.G. Correa, I.D. Bianco and C. Porporatto. 2018. Chitosan and cloxacillin combination improve antibiotic efficacy against different lifestyle of coagulase-negative staphylococcus isolates from chronic bovine mastitis. Scientific reports, 8(1): 1-13.
Carlson, R.P., R. Taffs, W.M. Davison and P.S. Stewart. 2008. Anti-biofilm properties of chitosan-coated surfaces. Journal of Biomaterials Science, Polymer Edition, 19(8): 1035-1046.
Christensen, G.D., W.A. Simpson, A.L. Bisno and E.H. Beachey. 1982. Adherence of slime-producing strains of staphylococcus epidermidis to smooth surfaces. Infection and immunity, 37(1): 318-326.
Costa, E., S. Silva, F. Tavaria and M. Pintado. 2017. Insights into chitosan antibiofilm activity against methicillin‐resistant staphylococcus aureus. Journal of applied microbiology, 122(6): 1547-1557.
Costa, E., S. Silva, S. Vicente, M. Veiga, F. Tavaria and M. Pintado. 2017. Chitosan as an effective inhibitor of multidrug resistant acinetobacter baumannii. Carbohydrate polymers, 178: 347-351.
Costa, E.M., S. Silva, C. Pina, F.K. Tavaria and M. Pintado. 2014. Antimicrobial effect of chitosan against periodontal pathogens biofilms. SOJ Microbiology & Infectious Diseases, 2(1): 1-6.
Donelli, G. and C. Vuotto. 2014. Biofilm-based infections in long-term care facilities. Future microbiology, 9(2): 175-188.
Edson, R.S. and C.L. Terrell, 1999. The aminoglycosides. In: Mayo Clinic Proceedings. Elsevier: pp: 519-528.
Felipe, V., M.L. Breser, L.P. Bohl, E.R. da Silva, C.A. Morgante, S.G. Correa and C. Porporatto. 2019. Chitosan disrupts biofilm formation and promotes biofilm eradication in staphylococcus species isolated from bovine mastitis. International Journal of Biological Macromolecules, 126: 60-67.
Foxman, B. 2002. Epidemiology of urinary tract infections: Incidence, morbidity, and economic costs. The American journal of medicine, 113(1): 5-13.
FR, W.C. 2012. Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement. Clinical and Laboratory Standards Institute, 32: M100.
Hassanshahi, G., A. Darehkordi, M.S. Fathollahi, S.K. Falahati-Pour, E.R. Zarandi and S. Assar. 2020. Resistance pattern of escherichia coli to levofloxacin in iran: A narrative review. Iranian Journal of Microbiology, 12(3): 177.
Huang, L., T. Dai, Y. Xuan, G.P. Tegos and M.R. Hamblin. 2011. Synergistic combination of chitosan acetate with nanoparticle silver as a topical antimicrobial: Efficacy against bacterial burn infections. Antimicrobial agents and chemotherapy, 55(7): 3432-3438.
Jakobsen, L., D. Sandvang, V.F. Jensen, A.M. Seyfarth, N. Frimodt‐Møller and A.M. Hammerum. 2007. Gentamicin susceptibility in escherichia coli related to the genetic background: Problems with breakpoints. Clinical microbiology and infection, 13(8): 830-832.
Karigoudar, R.M., M.H. Karigoudar, S.M. Wavare and S.S. Mangalgi. 2019. Detection of biofilm among uropathogenic escherichia coli and its correlation with antibiotic resistance pattern. Journal of laboratory physicians, 11(01): 017-022.
Magiorakos, A.-P., A. Srinivasan, R.B. Carey, Y. Carmeli, M. Falagas, C. Giske, S. Harbarth, J. Hindler, G. Kahlmeter and B. Olsson-Liljequist. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clinical microbiology and infection, 18(3): 268-281.
Martinez, L.R., M.R. Mihu, G. Han, S. Frases, R.J. Cordero, A. Casadevall, A.J. Friedman, J.M. Friedman and J.D. Nosanchuk. 2010. The use of chitosan to damage cryptococcus neoformans biofilms. Biomaterials, 31(4): 669-679.
Mathur, T., S. Singhal, S. Khan, D. Upadhyay, T. Fatma and A. Rattan. 2006. Detection of biofilm formation among the clinical isolates of staphylococci: An evaluation of three different screening methods. Indian journal of medical microbiology, 24(1): 25-29.
Mulvey, M.A., J.D. Schilling, J.J. Martinez and S.J. Hultgren. 2000. Bad bugs and beleaguered bladders: Interplay between uropathogenic escherichia coli and innate host defenses. Proceedings of the National Academy of Sciences, 97(16): 8829-8835.
Neupane, S., N.D. Pant, S. Khatiwada, R. Chaudhary and M.R. Banjara. 2016. Correlation between biofilm formation and resistance toward different commonly used antibiotics along with extended spectrum beta lactamase production in uropathogenic escherichia coli isolated from the patients suspected of urinary tract infections visiting shree birendra hospital, chhauni, kathmandu, nepal. Antimicrobial resistance and infection control, 5: 1-5.
Orgaz, B., M.M. Lobete, C.H. Puga and C.S. Jose. 2011. Effectiveness of chitosan against mature biofilms formed by food related bacteria. International Journal of Molecular Sciences, 12(1): 817-828.
Ponnusamy, P., V. Natarajan and M. Sevanan. 2012. In vitro biofilm formation by uropathogenic escherichia coli and their antimicrobial susceptibility pattern. Asian Pacific journal of tropical medicine, 5(3): 210-213.
Raafat, D., K. Von Bargen, A. Haas and H.-G. Sahl. 2008. Insights into the mode of action of chitosan as an antibacterial compound. Applied and environmental microbiology, 74(12): 3764-3773.
Rabea, E.I., M.E.-T. Badawy, C.V. Stevens, G. Smagghe and W. Steurbaut. 2003. Chitosan as antimicrobial agent: Applications and mode of action. Biomacromolecules, 4(6): 1457-1465.
Rafaque, Z., N. Abid, N. Liaqat, P. Afridi, S. Siddique, S. Masood, S. Kanwal and J.I. Dasti. 2020. In-vitro investigation of antibiotics efficacy against uropathogenic escherichia coli biofilms and antibiotic induced biofilm formation at sub-minimum inhibitory concentration of ciprofloxacin. Infection and Drug Resistance: 2801-2810.
Ramírez-Castillo, F.Y., A.C. Moreno-Flores, F.J. Avelar-González, F. Márquez-Díaz, J. Harel and A.L. Guerrero-Barrera. 2018. An evaluation of multidrug-resistant escherichia coli isolates in urinary tract infections from aguascalientes, mexico: Cross-sectional study. Annals of clinical microbiology and antimicrobials, 17(1): 1-13.
Sahariah, P. and M. Másson. 2017. Antimicrobial chitosan and chitosan derivatives: A review of the structure–activity relationship. Biomacromolecules, 18(11): 3846-3868.
Sharma, M., S. Yadav and U. Chaudhary. 2009. Biofilm production in uropathogenic escherichia coli. Indian Journal of Pathology and Microbiology, 52(2): 294.
Siddiqui, T., B. Naqvi, N. Alam, L. Bashir, S. Naz, G. Naqvi, M. Baig and S. Tasleem. 2013. Antimicrobial susceptibility testing of ciprofloxacin & cefepime against staphylococcus aureus & escherichia coli. International Journal of Scientific & Engineering Research, 4(12): 1386-1389.
Sundaramoorthy, N.S., P. Suresh, S. Selva Ganesan, A. GaneshPrasad and S. Nagarajan. 2019. Restoring colistin sensitivity in colistin-resistant e. Coli: Combinatorial use of marr inhibitor with efflux pump inhibitor. Scientific reports, 9(1): 19845.
Tin, S., K.R. Sakharkar, C.S. Lim and M.K. Sakharkar. 2009. Activity of chitosans in combination with antibiotics in pseudomonas aeruginosa. International Journal of Biological Sciences, 5(2): 153.
VA, A.R.S., S. Shenoy, T. Yadav and M. Radhakrishna. 2013. The antibiotic susceptibility patterns of uropathogenic escherichia coli, with special reference to the fluoroquinolones. Journal of clinical and diagnostic research: JCDR, 7(6): 1027.
Verlee, A., S. Mincke and C.V. Stevens. 2017. Recent developments in antibacterial and antifungal chitosan and its derivatives. Carbohydrate polymers, 164: 268-283.
Wang, A., Q. Wang, T. Kudinha, S. Xiao and C. Zhuo. 2016. Effects of fluoroquinolones and azithromycin on biofilm formation of stenotrophomonas maltophilia. Scientific Reports, 6(1): 29701.
Published
How to Cite
Issue
Section
Copyright (c) 2023 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
